VolitionRx Limited (NYSE American: VNRX) has announced a significant breakthrough in liquid biopsy technology, achieving over 99% purity in isolating circulating tumor-derived DNA using its Capture-Seq platform. This advancement addresses a longstanding challenge in liquid biopsy: distinguishing cancer DNA from healthy cell-free DNA in blood samples. The company reported strong early validation results, including no false positives and successful detection across initial study cohorts, supporting the potential of the technology as a novel biomarker approach.
The breakthrough could support applications in multi-cancer early detection and minimal residual disease monitoring, representing a combined total addressable market of approximately $36 billion. Volition is in active discussions with global diagnostic and liquid biopsy companies to accelerate development and commercialization of the platform. The company's technology focuses on epigenetics, studying chemical modifications to DNA that can indicate disease.
Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. The company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis.
For more details, the full press release is available at https://ibn.fm/1ZqGi. Additional information about the company can be found on its website at https://volition.com/.
